2 results
Approved WMOCompleted
To determine the toxicity of Zirconium-89 (Zr89) labelled Cetuximab in patient with stage IV cancer.
Approved WMOCompleted
The aim of this study is to quantify residual ER binding sites during fulvestrant therapy, compared to the tracer uptake prior to fulvestrant therapy.